Jackson Joseph W, Longstaff Colin, Woodle Samuel A, Chang William C, Ovanesov Mikhail V
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD, 20993-0002, United States of America.
National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire, UK.
Thromb J. 2023 Oct 4;21(1):104. doi: 10.1186/s12959-023-00549-5.
Fluorogenic thrombin generation (TG) is a global hemostasis assay that provides an overall representation of hemostasis potential. However, the accurate detection of thrombin activity in plasma may be affected by artifacts inherent to the assay-associated fluorogenic substrate. The significance of the fluorogenic artifacts or their corrections has not been studied in hemophilia treatment applications.
We sought to investigate TG in hemophilia plasma samples under typical and worst-case fluorogenic artifact conditions and assess the performance of artifact correction algorithms. Severe hemophilic plasma with or without added Factor VIII (FVIII) was evaluated using commercially available and in-house TG reagents, instruments, and software packages. The inner filter effect (IFE) was induced by spiking elevated amounts of fluorophore 7-amino-4-methylcoumarin (AMC) into plasma prior to the TG experiment. Substrate consumption was modeled by adding decreasing amounts of Z-Gly-Gly-Arg-AMC (ZGGR-AMC) to plasma or performing TG in antithrombin deficient plasma.
All algorithms corrected the AMC-induced IFE and antithrombin-deficiency induced substrate consumption up to a certain level of either artifact (edge of failure) upon which TG results were not returned or overestimated. TG values in FVIII deficient (FVIII-DP) or supplemented plasma were affected similarly. Normalization of FVIII-DP resulted in a more accurate correction of substrate artifacts than algorithmic methods.
Correction algorithms may be effective in situations of moderate fluorogenic substrate artifacts inherent to highly procoagulant samples, but correction may not be required under typical conditions for hemophilia treatment studies if TG parameters can be normalized to a reference plasma sample.
荧光凝血酶生成(TG)是一种全面的止血检测方法,可提供止血潜力的总体表征。然而,血浆中凝血酶活性的准确检测可能会受到与检测相关的荧光底物固有假象的影响。在血友病治疗应用中,荧光假象的意义或其校正方法尚未得到研究。
我们试图研究在典型和最坏情况的荧光假象条件下血友病血浆样本中的TG,并评估假象校正算法的性能。使用市售和自制的TG试剂、仪器和软件包,对添加或未添加凝血因子VIII(FVIII)的重度血友病血浆进行评估。在TG实验前,通过向血浆中加入过量的荧光团7-氨基-4-甲基香豆素(AMC)来诱导内滤光效应(IFE)。通过向血浆中加入递减量的Z-甘氨酰-甘氨酰-精氨酸-AMC(ZGGR-AMC)或在抗凝血酶缺乏的血浆中进行TG来模拟底物消耗。
所有算法都能将AMC诱导的IFE和抗凝血酶缺乏诱导的底物消耗校正到一定程度的假象(失败边缘),超过该程度则无法返回TG结果或结果被高估。FVIII缺乏(FVIII-DP)或补充血浆中的TG值受到类似影响。与算法方法相比,FVIII-DP的标准化能更准确地校正底物假象。
校正算法在高促凝样本固有的中度荧光底物假象情况下可能有效,但在血友病治疗研究的典型条件下,如果TG参数可以标准化到参考血浆样本,则可能不需要校正。